FluWatch report: August 24 to September 6, 2014 (Weeks 35 and 36)

Overall summary

  • Influenza activity in Canada remains at inter-seasonal levels with only sporadic detections of influenza.
  • In weeks 35 and 36 no outbreaks or hospitalizations were reported.
  • This is the first FluWatch report of the 2014-15 influenza season.

Are you a primary health care practitioner (General Practitioner, Nurse Practitioner or Registered Nurse) interested in becoming a FluWatch sentinel for the 2014-15 influenza season? Contact us at FluWatch@phac-aspc.gc.ca

On this page

Download the alternative format
(PDF format, 281 KB, 10 pages)

Organization: Public Health Agency of Canada

Date published: 2014-09-04

Influenza/ILI Activity (geographic spread)

In weeks 35 and 36, most regions in Canada reported no influenza/ILI activity. During these two weeks, one region in Quebec reported sporadic activity; and in week 36, two other regions (BC(1) and ON(1)) reported sporadic activity (Figure 1). In week 35, six regions did not report data, and in week 36, one region did not report.

Figure 1. Map of overall influenza/ILI activity level by province and territory, Canada, Week 36

Figure 1
Figure 1 Legend

Note: Influenza/ILI activity levels, as represented on this map, are assigned and reported by Provincial and Territorial Ministries of Health, based on laboratory confirmations, sentinel ILI rates and reported outbreaks. Please refer to detailed definitions at the end of the report. Maps from previous weeks, including any retrospective updates, are available on the Flu Activity website.

Figure 1 Map of overall influenza/ILI activity level by province and territory, Canada, Week 30 - Text Description
In week 36, three regions (BC(1), ON(1) and QC(1)) reported sporadic activity. No data was reported for one region (PE).

Influenza and Other Respiratory Virus Detections

The number of positive influenza tests continued at inter-seasonal levels in week 35 (5 detections) and week 36 (4 detections), with <1% of tests positive since early July (Figure 2). Most jurisdictions have reported only sporadic numbers of influenza detections in recent weeks (Table 1, Table 2).

Figure 2. Number of positive influenza tests and percentage of tests positive, by type, subtype and report week, Canada, 2014-15

Figure 2
   Figure 2 Number of positive influenza tests and percentage of tests positive, by type, subtype and report week, Canada, 2014-15 - Text Description

The number of positive influenza tests continued at inter-seasonal levels in week 35 (5 detections) and week 36 (4 detections), with <1% of tests positive since early July.

In weeks 35 and 36, detections of most other respiratory viruses were at inter-seasonal levels (RSV, coronavirus, and human metapneumovirus). Detections of parainfluenza, adenovirus and rhinovirus were in keeping with their usual pattern of seasonal circulation (figure 3).

For more details, see the weekly Respiratory Virus Detections in Canada Report.

Figure 3. Number of positive laboratory tests for other respiratory viruses by report week, Canada, 2014-15

Figure 3
RSV: Respiratory syncytial virus; hMPV: Human metapneumovirus
Figure 3 Number of positive laboratory tests for other respiratory viruses by report week, Canada, 2014-15 - Text Description
In weeks 35 and 36, detections of most other respiratory viruses were at inter-seasonal levels (RSV, coronavirus, and human metapneumovirus). Detections of parainfluenza, adenovirus and rhinovirus were in keeping with their usual pattern of seasonal circulation.
Table 1: Weekly and cumulative numbers of positive influenza specimens by type, subtype and province, Canada, 2014-15
Reporting provincesFootnote 1 Two weeks (August 24 to September 6, 2014) Cumulative (August 24 to September 6, 2014)
Influenza A B Influenza A B
A Total A(H1)pdm09 A(H3) A Footnote (Uns) B Total A Total A(H1)pdm09 A(H3) A(UnS) B Total
BC 0 0 0 0 0 0 0 0 0 0
AB 0 0 0 0 0 0 0 0 0 0
SK 0 0 0 0 0 0 0 0 0 0
MB 0 0 0 0 0 0 0 0 0 0
ON 2 0 1 1 1 2 0 1 1 1
QC 3 0 0 3 3 3 0 0 3 3
NB 0 0 0 0 0 0 0 0 0 0
NS 0 0 0 0 0 0 0 0 0 0
PE 0 0 0 0 0 0 0 0 0 0
NL 0 0 0 0 0 0 0 0 0 0
Canada 5 0 1 4 4 5 0 1 4 4
Percentage Footnote 2 55.6% 0.0% 20.0% 80.0% 44.4% 55.6% 0.0% 20.0% 80.0% 44.4%

Table 2. Weekly and cumulative numbers of positive influenza specimens by type, subtype and age-group reported through case-based laboratory reporting

Data suppressed for the 2014-15 season due to small values. Table 2 will be updated when additional data are received.

Influenza Strain Characterizations

The National Microbiology Laboratory (NML) has not yet reported any influenza strain characterizations for the 2014-15 season (Figure 4).

Figure 4. Influenza strain characterizations, Canada, 2014-2015, N = 0

The National Microbiology Laboratory (NML) has not yet conducted antigenic characterization of influenza viruses collected during the 2014-15 season.

The NML receives a proportion of the number of influenza positive specimens from provincial laboratories for strain characterization and antiviral resistance testing. Characterization data reflect the results of haemagglutination inhibition (HAI) testing compared to the reference influenza strains recommended by WHO.

The recommended components for the 2014-2015 northern hemisphere trivalent influenza vaccine include: an A/California/7/2009(H1N1)pdm09-like virus, an A/Texas/50/2012 (H3N2)-like virus, and a B/Massachusetts/2/2012-like virus (Yamagata lineage). For quadrivalent vaccines, the addition of a B/Brisbane/60/2008-like virus is recommended.

Antiviral Resistance

The NML has not yet reported antiviral resistance results for influenza viruses collected during the 2014-15 season (Table 3).

Table 3. Antiviral resistance by influenza virus type and subtype, Canada, 2014-15
Virus type and subtype Oseltamivir Zanamivir Amantadine
# tested # resistant (%) # tested # resistant (%) # tested # resistant (%)
A (H3N2) 0 0 0 0 0 0
A (H1N1) 0 0 0 0 0 0
B 0 0 0 0 NATable 3 - Footnote * NA Table 3 - Footnote *
TOTAL 0 0 0 0 0 0

Influenza-like Illness (ILI) Consultation Rate

The national influenza-like-illness (ILI) consultation rate increased from 8.0 consultations per 1,000 patient visits in week 34 to 13.6 per 1,000 in week 35 and decreased slightly to 12.3 per 1,000 in week 36 (Figure 5). The rates since mid-June have been above the expected range for this time of year.

Figure 5. Influenza-like-illness (ILI) consultation rates by report week, compared to the 1996-97 through to 2012-13 seasons (with pandemic data suppressed), Canada, 2014-2015

Figure 5

No data available for mean rate for weeks 19 to 39 for the 1996-1997 through 2002-2003 seasons. Delays in the reporting of data may cause data to change retrospectively. The calculation of the average ILI consultation rate over 17 seasons was aligned with influenza activity in each season. In BC, AB, and SK, data is compiled by a provincial sentinel surveillance program for reporting to FluWatch. Not all sentinel physicians report every week.

   Figure 5 Influenza-like-illness (ILI) consultation rates by report week, compared to the 1996-97 through to 2012-13 seasons (with pandemic data suppressed), Canada, 2015-16 - Text Description

The national influenza-like-illness (ILI) consultation rate increased from 8.0 consultations per 1,000 patient visits in week 34 to 13.6 per 1,000 in week 35 and decreased slightly to 12.3 per 1,000 in week 36. The rates since mid-June have been above the expected range for this time of year.

Influenza Outbreak Surveillance

No new outbreaks of influenza were reported in weeks 35 and 36 (Figure 6).

Figure 6: Overall number of new laboratory-confirmed influenza outbreaks by report week, Canada, 2014-2015

Figure 6

1 All provinces and territories except NU report outbreaks in long-term care facilities. All provinces and territories with the exception of NU and QC report outbreaks in hospitals. Outbreaks of influenza or influenza-like-illness in other facilities are reported to FluWatch but reporting varies between jurisdictions. Outbreak definitions are included at the end of the report.

Figure 6 Overall number of new laboratory-confirmed influenza outbreaks by report week, Canada, 2015-2016 - Text Description
Report week Hospitals Long Term Care Facilities
35 0 0
36 0 0

Pharmacy surveillance

In weeks 35 and 36, the proportion of prescriptions for antivirals was at inter-seasonal levels (Figure 7).

Figure 7. Proportion of prescription sales for influenza antivirals by age-group and week, Canada, 2014-15

Figure 7

Note: Pharmacy sales data are provided to the Public Health Agency of Canada by Rx Canada Inc. and sourced from major retail drug chains representing over 2,500 stores nationwide (excluding Nunavut) in 85% of Health Regions. Data provided include the number of new antiviral prescriptions (for Tamiflu and Relenza) and the total number of new prescriptions dispensed by Province/Territory and age group. Age-groups: Infant: 0-2y, Child: 2-18y; Adult: 19-64y, Senior: ≥65y

Figure 7 Proportion of prescription sales for influenza antivirals by age-group and week, Canada, 2015-16 - Text Description

Proportion of antiviral prescriptions per 100,000 total prescriptions in week 36 for the current season compared to previous seasons:
2014-15: 5.2; 2013-14: 5.1; 2012-13: 4.3; 2011-12: 4.4
Proportion of antiviral prescriptions by age-group in week 36 for the 2014-15 season:
Infant: 0.0; child: 5.7; adult: 6.6; senior: 2.2

Sentinel Hospital Influenza Surveillance

Paediatric Influenza Hospitalizations and Deaths (IMPACT)

No laboratory-confirmed influenza-associated paediatric (≤16 years of age) hospitalizations have been reported by the Immunization Monitoring Program Active (IMPACT) network for the 2014-15 season (Figure 8a).

Note: The number of hospitalizations reported through IMPACT represents a subset of all influenza-associated paediatric hospitalizations in Canada. Delays in the reporting of data may cause data to change retrospectively.

Adult Influenza Hospitalizations and Deaths (PCIRN)

Surveillance of laboratory-confirmed influenza-associated adult (≥16 years of age) hospitalizations by the PHAC/CIHR Influenza Research Network (PCIRN) Serious Outcomes Surveillance (SOS) network has not yet begun for the 2014-15 season (Figure 8B).

Note: The number of hospitalizations reported through CIRN represents a subset of all influenza-associated adult hospitalizations in Canada. Delays in the reporting of data may cause data to change retrospectively.

Table 4 - Cumulative numbers of paediatric hospitalizations with influenza reported by the IMPACT network, Canada, 2014-15
Age groups Cumulative (Aug. 24, 2014 to September 6, 2014)
Influenza A B Influenza A and B
A Total A(H1) pdm09 A(H3) AFootnote (Uns) Total # (%)
0-5m 0 0 0 0 0 0
6-23m 0 0 0 0 0 0
2-4y 0 0 0 0 0 0
5-9y 0 0 0 0 0 0
10-16y 0 0 0 0 0 0
Total 0 0 0 0 0 0
% Footnote 1 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%

Table 5 - Cumulative numbers of adult hospitalizations with influenza reported by the PCIRN-SOS network, Canada, 2014-15

PCIRN-SOS surveillance for the 2014-15 season has not yet begun.

Figure 8 - Number of cases of influenza reported by sentinel hospital networks, by week, Canada, 2014-15

A) Paediatric hospitalizations (≤16 years of age, IMPACT)

Figure 8A
Figure 8A Number of cases of influenza reported by sentinel hospital networks, by week, Canada, 2015-16 - Text Description
Report week Influenza A Influenza B
35 0 0
36 0 0

Figure 8B - Number of cases of influenza reported by sentinel hospital networks, by week, Canada, 2014-15

B) Adult hospitalizations (≥16 year of age, PCIRN-SOS)

Figure 8B
Figure 8B Number of cases of influenza reported by sentinel hospital networks, by week, Canada, 2015-16 - Text Description
Report week Influenza A Influenza B Untyped
35 n/a n/a n/a
36 n/a n/a n/a

Figure 9 - Percentage of hospitalizations, ICU admissions and deaths with influenza reported by age-group, Canada, 2014-15

A) Paediatric hospitalizations (≤16 years of age, IMPACT)

Figure 9a
Figure 9A Percentage of hospitalizations, ICU admissions and deaths with influenza reported by age-group, Canada, 2014-15 A) Paediatric hospitalizations (≤16 years of age, IMPACT) - Text Description
Age-group (years) Hospitalizations(n=0) ICU admissions(n=0)
0-5m 0 0
6-23m 0 0
2-4y 0 0
5-9y 0 0
10-16y 0 0

Adult hospitalizations (≥16 year of age, PCIRN-SOS)

Figure 9b
Figure 9B Percentage of hospitalizations, ICU admissions and deaths with influenza reported by age-group, Canada, 2014-15 B) Adult hospitalizations (≥16 year of age, CIRN) - Text Description
Age-group (years) Hospitalizations (n=0) ICU admissions(n=0) Deaths (n=0)
16-20 0 0 0
20-44 0 0 0
45-64 0 0 0
65+ 0 0 0

Provincial/Territorial Influenza Hospitalizations and Deaths

No laboratory-confirmed influenza-associated hospitalizations have been reported from participating provinces and territoriesFootnote * since the start of the 2014-15 season.

Table 6. Cumulative number of hospitalizations with influenza reported by the participating provinces and territories, Canada, 2014-15
Age groups Cumulative (24 August 2014 to 1 August 2015)
Influenza A B Influenza A and B
A Total A(H1) pdm09 A(H3) AFootnote (Uns) Total # (%)
0-4 years 0 0 0 0 0 0
5-19 years 0 0 0 0 0 0
20-44 years 0 0 0 0 0 0
45-64 years 0 0 0 0 0 0
65+ years 0 0 0 0 0 0
Unknown 0 0 0 0 0 0
Total 0 0 0 0 0 0
Percentage Footnote 1 0% 0% 0% 0% 0% 0%

See additional data on Reported Influenza Hospitalizations and Deaths in Canada: 2009-10 to 2014-15 on the Public Health Agency of Canada website.

Emerging Respiratory Pathogens

Human Avian Influenza
Influenza A(H7N9): No new cases of human infection with influenza A(H7N9) have been reported by the World Health Organization since the last FluWatch report. Globally to September 11, 2014, the WHO has been informed of a total of 453 laboratory-confirmed human cases with avian influenza A(H7N9) virus, including 175 deaths.

Documents related to the public health risk of influenza A(H7N9), as well as guidance for health professionals and advice for the public is updated regularly on the following websites:

PHAC - Avian influenza A(H7N9)
WHO - Avian Influenza A(H7N9)

Middle East Respiratory Syndrome Coronavirus (MERS-CoV)

Globally, from September 2012 to September 11, 2014, the WHO has been informed of a total of 841 laboratory-confirmed cases of infection with MERS-CoV, including 298 deaths. All cases have either occurred in the Middle East or have had direct links to a primary case infected in the Middle East. The public health risk posed by MERS-CoV in Canada remains low (see the PHAC Assessment of Public Health Risk).

Documents related to the public health risk of MERS-CoV, as well as guidance for health professionals and advice for the public is updated regularly on the following websites:

International Influenza Reports


FluWatch definitions for the 2014-2015 season

Abbreviations: Newfoundland/Labrador (NL), Prince Edward Island (PE), New Brunswick (NB), Nova Scotia (NS), Quebec (QC), Ontario (ON), Manitoba (MB), Saskatchewan (SK), Alberta (AB), British Columbia (BC), Yukon (YT), Northwest Territories (NT), Nunavut (NU).

Influenza-like-illness (ILI): Acute onset of respiratory illness with fever and cough and with one or more of the following - sore throat, arthralgia, myalgia, or prostration which is likely due to influenza. In children under 5, gastrointestinal symptoms may also be present. In patients under 5 or 65 and older, fever may not be prominent.

ILI/Influenza outbreaks

Schools:
Greater than 10% absenteeism (or absenteeism that is higher (e.g. >5-10%) than expected level as determined by school or public health authority) which is likely due to ILI.
Note: it is recommended that ILI school outbreaks be laboratory confirmed at the beginning of influenza season as it may be the first indication of community transmission in an area.
Hospitals and residential institutions:
two or more cases of ILI within a seven-day period, including at least one laboratory confirmed case. Institutional outbreaks should be reported within 24 hours of identification. Residential institutions include but not limited to long-term care facilities ( LTCF) and prisons.
Workplace:
Greater than 10% absenteeism on any day which is most likely due to ILI.
Other settings:
two or more cases of ILI within a seven-day period, including at least one laboratory confirmed case; i.e. closed communities.

Note that reporting of outbreaks of influenza/ILI from different types of facilities differs between jurisdictions.

Influenza/ILI activity level

1 = No activity: no laboratory-confirmed influenza detections in the reporting week, however, sporadically occurring ILI may be reported

2 = Sporadic: sporadically occurring ILI and lab confirmed influenza detection(s) with no outbreaks detected within the influenza surveillance region Footnote

3 = Localized:

  1. evidence of increased ILIFootnote * and
  2. lab confirmed influenza detection(s) together with
  3. outbreaks in schools, hospitals, residential institutions and/or other types of facilities occurring in less than 50% of the influenza surveillance regionFootnote

4 = Widespread:

  1. evidence of increased ILIFootnote * and
  2. lab confirmed influenza detection(s) together with
  3. outbreaks in schools, hospitals, residential institutions and/or other types of facilities occurring in greater than or equal to 50% of the influenza surveillance regionFootnote

Note: ILI data may be reported through sentinel physicians, emergency room visits or health line telephone calls.

Report a problem or mistake on this page
Please select all that apply:

Privacy statement

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: